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Effects of different treatment regimens of methylprednisolone
on rat diaphragm contractility, immunohistochemistry
and biochemistry
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Effects o f different treatment regimens o f methylprednisolone on rat diaphragm con­
tractility, immunohistochemistry and biochemistry. R.H.H. van Balkom, H.F.M. van der 
Heijden, H.T.B. van Moerkerk, J.H. Veerkamp, JA M . Fransen, L.Â. Ginsel, H.Th.M. 
Folgering, C,LA. van Herwaarden, P.N.R. Dekhuijzen. ©ERS Journals Ltd 1996, ABSTRACT: Systemic corticosteroid therapy may affect diaphragm structure and 
function. We postulated that functional, immunohistochemical and biochemical char­
acteristics of rat diaphragm were less affected by altemate-day methylprednisolone 
(MP) administration, and more by repeated bursts of MP, in comparison to daily 
s*c MP.
Sixty adult rats were randomized into four groups: saline s.c.; MP continuously 
(MP-C), 1 mg »kg“1 daily, MP alternate-day therapy (MP-A), 2 mg» kg-1 every other 
day; or MP in bursts (MP-B), MP 2 mg»kg"1 daily for 2 weeks, saline for 4 weeks, 
MP 2 mg-kg"1 daily for 2 weeks. The total treatment period was 8 weeks. Contractile 
properties of isolated diaphragm strips were measured. Antibodies reactive with 
type I, Ila, Ilx and üb myosin heavy chains were used for immunohistochemical analysis. Biochemical evaluation included markers of fast energy supply, glycogeno­
lytic activity, ß-oxidation capacity and oxidative capacity.The force-frequency curve was depressed in all MP groups. Fibre type I, Ilx and 
Hb cross-sectional area (CSA) decreased in all MP groups. Burst therapy decreased the contribution of type lib  fibres to total diaphragm muscle area. MP-A affected 
glycogenolytic activity less than MP-C. Burst MP therapy reduced creatine kinase 
(CK) activity and ß-oxidation capacity compared to MP-C. Oxidative capacity was 
increased in all MP groups.
In conclusion, although the methylprednisolone treatment regimens affected 
diaphragm muscle morphology and bioenergetic enzyme activities in different ways, 
force generation decreased in all methylprednisolone treated groups to the same 
extent.
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Recently, animal and clinical studies have shown evi­
dence of respiratory muscle dysfunction induced by treat­
ment with corticosteroids [1,2]. Morphological changes, 
such as selective type lib fibre atrophy, were observed 
in animal studies following administration of fluorina- 
ted steroids [3,4]. Nonfluorinated steroids, however, caused 
loss of diaphragm function without muscle atrophy, sug­
gesting myopathy [4].
The mechanisms by which nonfluorinated steroids cause 
myopathy are in part unknown. Changes in myosin heavy 
chain composition in the muscle fibres may contribute, 
since myosin heavy chain turnover rate in muscle cells 
was decreased following dexamethasone therapy [5]. 
These myosin heavy chains determine myosin adenosine 
triphosphatase (ATP-ase) activity and the speed of shorte­
ning in the muscle fibres and are, therefore, partly respon­
sible for contractile properties. P o l la  et a l [6] reported 
a complete disappearance of rat diaphragm muscle fibres 
containing Hb myosin heavy chains (MyHCs) following 
cortisone acetate 100 mg-kg-^day1 for 11 days. It is not
known whether similar changes occur after administra­
tion of lower, clinically more relevant dosages.
Changes in energy substrate and enzyme activities 
may also contribute to the onset of steroid-induced myopa­
thy. A consistent observation is the increase in glycogen 
content in the diaphragm [7, 8]. However, conflicting 
effects on diaphragm mitochondrial function were found 
following corticosteroid therapy [9, 10]. This may be 
explained by the differences in the dosage, duration, and 
types of steroids studied.
In addition, the severity of structural and biochemical 
changes in the respiratory muscles may depend on the 
treatment regimens applied. Alternate-day glucocorticoid 
therapy may reduce side-effects, since anti-inflamma- 
tory potency appears to persist longer than the undesir­
able metabolic effects [11, 12], The clinical efficacy of 
altemate-day therapy was similar in patients with chronic 
obstructive pulmonary disease (COPD) or stable asthma 
compared to daily treatment [13, 14]. Another treatment 
regimen, short-term high-dose steroid therapy is often
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applied during exacerbations of COPD or asthma. Repea­
ted episodes of high-dose steroid administration, in this 
study referred to as "burstsM, may cause more severe side- 
effects. This concept is supported by the observation that 
recovery from acute steroid myopathy, caused by short- 
time high-dose steroid administration, appears to take 
several months [15]. Such a prolonged recovery period 
was also shown in a recent animal study [16].
We postulate that the structure and function of the rat 
diaphragm: 1) is less affected by altemate-day corticos­
teroid administration; and 2) is more affected by repea­
ted bursts, in comparison to daily administration. In order 
to test this hypothesis, we studied functional, immuno­
histochemical and biochemical changes in rat diaphragm 
induced by continuous, altemate-day and burst admini­
stration of the nonfluorinated steroid, methylpredniso­
lone.
Methods
Study design, animals and treatment
Sixty adult male outbred Wistarrats, aged 18-20 weeks, 
mean (±sd) weight 525±35 g, were randomized into four 
groups:
control (C), saline 0.2 mL-dayl s.c.; 
methylprednisolone (MP) continuously (MP-C), MP 1 
mg-kg^-day4 s.c.;
MP altemate-day therapy (MP-A), MP 2 mg-kg“1 s.c. 
every other day alternating with saline 0.2 mL s.c.; MP 
in bursts (MP-B), MP 2 mg-kg-May1 s.c. for 2 weeks 
followed by saline 0.2 mL s.c. for 4 weeks and by MP
2 mg-kg^-day1 s.c. for 2 weeks.
Each injection was of similar volume (-0.2 mL). Over 
8 weeks, the animals were injected s.c. daily between 
8.30 h and 1000 h in the neck. The total dose of steroids 
administered was equal in all treatment groups. The rats 
were fed ad libitum, maintained on a 12/12 h light-dark 
regimen, and weighed twice weekly. At the end of the 
treatment period, contractile properties, immunohisto­
chemical and biochemical characteristics of the diaphragm 
were examined. All animals were investigated between 
23 and 30 h after the last injection. Adrenal and diaphragm 
weights were measured immediately following dissec­
tion. The study was approved by the local Animal Experi­
ments Committee of the University of Nijmegen.
Contractile properties
The rats were anaesthetized with sodium pentobarbital 
(70 mg'kg-1 Lp.) and a polyethylene cannula was inser­
ted through a tracheotomy. The animals were mechani­
cally-ventilated with an oxygen-enriched gas mixture 
(airflow 0,5 m L g 1 body weight-min-1, respiratory freque­
ncy 70 breaths-mnr1, and a duty cycle 50%). The diaph­
ragm was quickly removed through a combined laparotomy 
and thoracotomy and was immediately immersed in a 
cooled, oxygenated Krebs solution at a pH of 7.4. This 
solution consisted of (mmol-L'1): 137 NaCl, 4 KC1, 2
MgCl2, 1 KH2P 04, 24 NaHC03, 2.7 CaCl2, and 7 glu­
cose. D-tubocurarine chloride 25 pM (Sigma Chemicals, 
The Netherlands) was added to prevent spontaneous neuro­
muscular activity.
Two small rectangular bundles, parallel to the long 
axis of the muscle fibres, were dissected from the middle 
part of the lateral costal region of each hemidiaphragm. 
Silk sutures were firmly tied to both ends of the bundle 
to serve as anchoring points. Each bundle was placed in 
a tissue bath between two large platinum stimulating 
electrodes. The tissue baths were filled with Krebs solu­
tion at 37°C and were oxygenated with 95% 0 2 and 5% 
C02. The central tendon insertion of the bundles was 
tied to a fixed point and the costal margin origin to an 
isometric force transducer (Sensotec, model 31/1437; 
Columbus, OH, USA). Data acquisition and storage were 
performed using a Dash-16 interface and Twist-Trigger 
software (I.D.-electronics, University of Nijmegen, The 
Netherlands). Stimulations were applied with a Grass S 
48 stimulator (Quincy, MA, USA). Maximal twitch force 
was reached at 34 V. To ensure supramaximal stimula­
tion, subsequent stimulations were performed with a 20% 
higher voltage (40 V). The pulse duration was set on 0.2 
ms. Twitch stimuli were used to determine the optimal 
length (Lo), followed by a 15 min thermoequilibration per­
iod [17]. The following measurements were made.
Twitch characteristics. Two twitches were recorded at Lo 
to obtain maximal twitch tension (Pt), contraction time 
(CT), and half relaxation time (1/2RT). The averages were 
used for further analysis.
Maximal tetanic contraction. Two maximal tetanic stim­
uli (with a frequency of 160 Hz and a train duration of 
250 ms) were generated to obtain maximal tetanic ten­
sion (Po),
Force-frequency (FF) protocol. Muscle bundles were 
stimulated every 2 min with the following order of fre­
quencies: 25, 160, 50, 160, 80, 160, 120 and 160 Hz 
(train duration 250 ms). Forces were also expressed as 
percentage of the average force at 160 Hz before and 
after each stimulus [4, 18].
The generated force was expressed per cross-sectional 
area (kg-cmr2). Cross-sectional area (CSA) was measured 
by dividing diaphragm bundle weight by muscle den­
sity (1.056 mg-mnr3) and bundle length.
Immunohistochemical procedures
Muscle strips obtained from the costal part of the right 
hemidiaphragm were embedded in Tissue-Tek® in a plas­
tic holder. The muscle fibres were oriented parallel to 
the long side of the holder. Subsequently, these speci­
mens were quickly frozen in isopentane cooled in liquid 
N2, followed by further freezing in liquid N2. Serial cross- 
sections were cut at 7 jam with a cryostat kept at -30°C. 
Antimyosin heavy chain antibodies (Regeneran Pharma­
ceuticals, New York, USA) were used for morphometric 
examination. The following antibodies were used: BA­
DS reactive with type I MyHCs; SC-71 reactive with 
type Ha MyHCs; BF-35 reactive with type I, Ila and üb 
but not with type IIx MyHCs; and BF-F3 reactive with
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type üb MyHCs [19]. Incubation with antimyosin heavy 
chain antibodies was performed at room temperature for 
1 h. Antibodies were subsequently labelled with ultra 
small immunogold reagent followed by silver enhance­
ment (Aurion, Wageningen, The Netherlands). A mini­
mum of 300 fibres was analysed from each diaphragm 
using a Sprynt-based, PC-Image digital analysis system 
(Bos B.V., Waddinxveen, The Netherlands).
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Biochemistry
Parameters of the bioenergetic capacity of the diaphragm 
included the activities of creatine kinase (CK), respon­
sible for the fast energy supply, the glycogenolytic 
enzyme phosphorylase, and the mitochondrial enzymes 
3-hydroxyacyl-CoA dehydrogenase (HADH), a marker 
for the ß-oxidation capacity, and citrate synthase (CS), 
an index of citric acid cycle activity.
Fat and tendon were quickly removed from remains 
of the left and right hemidiaphragm. Subsequently, these 
diaphragm parts were frozen in liquid N2 and stored at 
-80°C. Segments of freshly frozen diaphragm were 
thawed in ice-cooled buffer containing 250 mM sucrose, 
2 mM ethylenediamine tetra-acetic acid (EDTA) and 10 
mM Tris-HCl (pH 7.4). In this buffer, muscle homogen- 
ates (5% wt-vol_1) were prepared by hand homogeniza- 
tion, using a Potter-Elvehjem glass-teflon homogenizer.
CK activity was determined with the Boehringer CK- 
NAC activated kit [20], and expressed in mmol reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) 
formed-min-^g tissue. Total phosphorylase (a+b) acti­
vity was assayed according to the method described by 
J a c o b s  and co-workers [20]. Phosphorylase activity 
was expressed as i^mol NADPH formed^min  ^g tissue. 
HADH activity was assessed at 50 jjM acetoacyl-CoA 
[22] and expressed in nmol HADH oxidizedmhrl g tis­
sue. CS activity was determined at 25°C [23], and was 
expressed as pmol coenzyme A (CoA) formed-min ^g 
tissue. All other above-mentioned measurements were 
performed at 37°C. The assays for metabolic enzymes 
were performed spectrophotometrically in duplicate. The 
coefficient of variation for the assays applied was -5%.
Data analysis
Data of contractile properties of the two bundles obtained 
from one rat were averaged. The Statistical Package for 
the Social Sciences (SPSS)/PC+ package V5.0.1 (Chicago, 
111, USA) was used for statistical analysis. Data were 
compared using one-way analysis of variance (ANOVA) 
followed by Duncan's multiple-range test. Repeated mea­
sures ANOVA was used for growth curve analysis, and 
a two-way ANOVA was used to detect treatment dif­
ferences in force generation during the FF protocol. 
Results were considered significant at p-values less than 
0.05. Data are expressed as mean±SD.
Results
Body, muscle and adrenal weight
Figure 1 shows the body weight curve during the 8 
week treatment period. A significant effect of steroid
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Fig. 1. -  Mean growth curve for the four groups. —o— : control; 
—0— : MP-C; —□— : MP-A; —A— : M P-B;-------: pooled stan­
dard deviation (p =0.039). MP: methylprednisolone; MP-C: MP con­
tinuously, 1 mg-kg’1 daily; MP-A: MP alternate day therapy, 2 mg*kg4 
every other day; MP-B: MP in bursts, 2 mg-kg-1 daily for 2 weeks, 
saline for 4 weeks, MP 2 mg kg-1 for 2 weeks.
treatment on growth curve was noted throughout this per­
iod (p=0.039). Continuous MP administration affected 
body growth most. Body weights of the MP-A animals 
closely tracked those of the control group. Administra­
tion in bursts temporarily inhibited growth.
No differences in absolute diaphragm weights were ob­
served. Diaphragm weight, normalized for body weight, 
was also similar in all groups (Control 0.0132±0.001%; 
MP-C 0.0143±0.001%; MP-A 0.0136±0.001%; MP-B 
0.0141±0.002%). Absolute adrenal weight was reduced 
in all MP treatment groups. Adrenal weights in the treat­
ment groups were reduced in proportion to body weight 
(Control 0.0082±0.0014%; MP-C 0.0077±0.0008%; MP- 
A 0.0074±0.0007%; MP-B 0.0079±0.00l%).
Contractile properties
Diaphragm bundle dimensions did not differ between 
the four groups (average length -16.5 mm, thickness -0.67 
mm, width -1.8 mm, and weight -26  mg). Pt and Po, 
normalized for CSA, decreased by 7.0--9.5% in all MP 
groups (p=0.07). Twitch characteristics did not differ 
between the groups (table 1).
The FF curves, expressed as absolute values, showed 
significant differences in force generation (p=0.026) in 
all groups treated with MP. Force generation was equ­
ally reduced in all MP groups (fig. 2), MP treatment affec­
ted force generation at all stimulation frequencies in a 
similar way. The percentage decrease in force production 
of the final 160 Hz stimulation during the FF protocol 
was similar in the three MP groups, and did not differ 
from control (MP-C 11.4±10.0%; MP-A 11.7±7.5%; MP- 
B 12.5±11.0%; Control 9.0±7.7%).
Immunohistochemistry
Methylprednisolone administrated in bursts (MP-B) 
caused a shift in fibre distribution from type lib to type 
IIx in comparison to control (p<0.05) (table 2).
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Table 1. -  Diaphragm contractile properties
Treatment Pi
kg*cnv2
CT
ms
1/2RT
ms
Po
kg'cm'2 PtIPo
Control 0.64 (0.18) 29.3 (1.8) 17.7 (1.3) 2.23 (0.51) 0.29 (0.03)
MP-C 0.58 (0.20) 28.8 (2.1) 17.9 (1) 2.02 (0.65) 0.29 (0.02)
MP-A 0.60 (0.15) 29.2 (2.3) 18.1 (1.1) 2.07 (0.42) 0.29 (0.03)
MP-B 0.59 (0.23) 29.2 (2.6) 18.1 (1.6) 2.02 (0.74) 0.29 (0.04)
Pt: twitch tension; CT: contraction time; 1/2RT: half relaxation time; Po: maximal tetanic tension; MP: methyl- 
prednisolone; MP-C: MP continuously, 1 mg «kg“1 daily; MP-A: MP altemate-day therapy, 2 mg-kg*1 every 
other day; MP-B: MP in bursts, 2 mg-kg-1 daily for 2 weeks, saline for 4 weeks, MP 2 mg-kg'1 for 2 weeks.
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Fig. 2. -  Force-frequency curve, —o—
—o— : MP-A; —▲— : M P-B;-------:
For abbreviations see legend to figure 1.
: control; —■— : MP-C; 
pooled standard deviation.
Significant atrophy of type I, IIx and Hb fibres was 
observed in all MP groups (fig. 3). The differences in 
type Ha fibre CSA, as shown in figure 3, were signifi­
cant but very small. The degree of type Ebt atrophy was 
less following altemate-day in comparison to continuous 
MP therapy. In addition, type IIx CSA decreased in the 
MP-B group compared to MP-C. Thus, type IIx fibre 
atrophy was most pronounced following bursts and least 
affected by altemate-day steroid therapy compared to 
daily treatment (fig. 3). In contrast, the degree of type 
Hb fibre atrophy was greater in the MPA animals com­
pared to MP-C.
As a result of the decrease in number of type üb fibres 
in the MP-B group, the relative contribution of type Hb 
fibres to the total muscle area of the diaphragm was 
decreased compared to control (fig. 4).
Table 2. -  Fibre type distribution
Type I Type Ila Type Hx Type Hb
Treatment % % % %
Control 32.7 (4.1) 33.5 (4.2) 28.3 (4.1) 5.5 (4.3)
MP-C 33.4 (3.6) 3L6 (6.1) 31.4 (4.2) 3.7 (3.7)
MP-A 34.6 (3.5) 33.4 (3.9) 28.7 (3.5) 3.3 (3.6)MP-B 33.6 (3.1) 31.5 (3.5) 33.2 (4.9)# 1.8 (2.0)*
*: p<0.05, compared to control; pcO.05, compared to control 
and the MP-A group. For abbreviations see legend to table 1.
6000'
5000-
4000“«Ë=S.
O
3000-
2000-
1000-
0-
I Ila IIx lib
Fibre type
Fig. 3. -  Fibre type cross-sectional area (CSA). □  : control; K3 : 
MP-C; E3 : MP-A; U  ; MP-B. *: p<0.05, compared to control; #:
pcO.OS, compared to MP-C. For abbreviations see legend to figure 1.
Biochemistry
The data on bioenergetic enzyme activities are shown 
in table 3. An approximately 30% increase in CS acti­
vity was found in all MP treatment groups, indicating an 
increased oxidative capacity (p<0.01).
Treatment with the three MP regimens affected energy 
supply by different mechanisms. Firstly, continuous steroid
60-
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Fig. 4. -  Relative fibre type contribution to the total muscle area of 
the diaphragm. □  : control; EZJ: MP-C; E3: MP-A; BBS : MP-B. *: 
pcO.OS, compared to control. For abbreviations see legend to figure 1.
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Table 3. -  Biochemical analysis of the diaphragm
Treatment
CK
kUg-1 Phosphorylaseu - r 1
HADH
U-g-i
CS
U-g-'
Control 2.18 (0.54) 35.5 (3.3) 2.86 (0.44) 23.9 (2.3)
MP-C 1.82 (0.64) 32.6 (2.0)# 2.83 (0.66) 30.8 (6.5)*MP-A 1.48 (0.32)* 38.0 (3.2) 2.84 (0.51) 31.2 (4.0)*
MP-B 1.39 (0.47)*t 37.2 (4.0) 2.24 (0.35)# 30.6 (4.8)*
CK: creatine kinase; HADH: 3-hydroxyacyl-CoA dehydrogenase; CS: citrate synthase. For fur­
ther abbreviations see legend to table 1. *: p<0,01, compared to control; p. p<0.05, compared 
to MP-C; p<0.0l, compared to all other groups.
administration decreased glycogenolytic activity, indi­
cated by a decrease in phosphorylase activity. Secondly, 
glycogenolytic activity was less affected following alter- 
nate-day steroid administration in comparison to daily 
treatment. Finally, burst MP administration affected CK 
activity and ß-oxidation capacity, as indicated by HADH, 
more in comparison to MP-C. Total phosphorylase acti­
vity, however, was higher in the MP-B group than in the 
MP-C group.
Discussion
The question in the present study was whether there 
were differences in changes in rat diaphragm following 
different corticosteroid treatment regimens. The data 
showed that the MP treatment regimens affected body 
weight, diaphragm morphology and bioenergetic capa­
city in a different way. Force generation, however, decrea­
sed to a similar extent in all MP treatment regimens. This 
apparent discrepancy can be explained by the fact that 
the net result of these combined morphometric and bio­
chemical changes was an equal reduction in force gen­
eration.
Rationale o f methylprednisolone dosage
The rationale for the dose of MP used in the present 
study was based on an absorption of 60% after i.m. injec­
tion [18], and the finding that the s.c. route may require 
higher doses to produce effects similar to i.m. adminis­
tration [24]. Similar anti-inflammatory potency and meta­
bolism of methylprednisolone have been described in rats 
and humans [25, 26]. Therefore, 1 mg-kg-1 of MP, as 
administrated in the MP-C group, may be equivalent to 
a dose o f 35 mg*day-1 in a 60 kg human. A daily dose 
of 35 mg methylprednisolone is not uncommon in the 
treatment of patients with COPD during an exacerbation
[27].The duration of biological effects of methylpredniso­
lone in rat is difficult to analyse because of the nonlin­
ear clearance [28]. In addition, no close correlation was 
found between the circulating half-life of a glucocorti­
coid and its duration of action [12]. However, the dif­
ferences in growth curves observed in the present study 
indicate that there are differences in biological effects 
between continuous and alternate-day therapy.
Contractile properties
The reduction in diaphragm force generation follow­
ing MP therapy, observed in this study during the FF
protocol, cannot be explained by differences in oxy­
genation of the bundles, since their measures were simi­
lar in all groups. Since MP has little or no mineralocorticoid 
activity, an overestimation of the CSA due to an increase 
in extracellular fluid is unlikely. Glucocorticoids are known 
to cause protein wasting [29], A reduction in myofibril­
lar protein density would result in a reduction in the num­
ber of cross-bridges available for interaction with actin. 
This can lead to a reduction in force generation. Other 
plausible causes for the impairment in diaphragm force 
are the morphological and biochemical changes.
In previous studies, no changes in twitch and maxi­
mal tetanic tension were found following 0.5 mg-kg-1 
daily MP for 6 weeks [17], or following 5 mg-kg-1 daily 
prednisolone for 4 weeks [4]. In addition, cortisone ace­
tate, 100 mg-kg-1-day-1 for 10 days, did not lead to func­
tional changes in the diaphragm [18]. The downward 
shift of the FF curve in the present study may be explained 
by differences in effects of dosage and duration of the 
steroid therapy on morphological and biochemical char­
acteristics (see below).
Immunohistochemistry
Immunohistochemical differentiation between type IIx 
and lib fibres, as performed in this study, may be of 
importance since type IIx and lib MyHCs possess bio­
chemical and functional differences. Maximum velocity 
of shortening [30] and resistance to fatigue [31] in type 
Hx muscle fibres are intermediate between those of type 
Ila and Hb fibres. Twitch and tetanic tension are higher 
in lib in comparison with Ila and nx motor units [31]. 
Type nx muscle fibres have a rich mitochondrial con­
tent, in contrast to type Hb fibres [19],
In support of our hypothesis, the degree of type nx 
atrophy was less following altemate-day MP adminis­
tration compared to continuous therapy. On the other 
hand, type Hb fibre atrophy was more pronounced in the 
altemate-day group. Cortisone acetate treatment in rab­
bits resulted in atrophy of all diaphragm fibre types [32], 
whereas no changes in fibre CSA were found in rats fol­
lowing prednisolone treatment [4]. Muscle fibre atrophy 
can be the result of steroid-induced protein wasting due 
to a reduction in protein synthesis and an increase in 
intracellular proteolysis [29]. However, muscle fibre atro­
phy may also occur as an attempt to increase oxygen 
delivery by decreasing the cell diameter, in this way cre­
ating a smaller diffusion distance [33].
Burst therapy reduced the number of type lib fibres 
and decreased the contribution of type üb fibres to total
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diaphragm muscle area. Cortisone acetate administration 
(100 mg-kg*1 daily for 11 days) actually resulted in a com­
plete disappearance of fibres containing Hb MyHCs, while 
fibre type distribution was not described [6]. These 
changes were not detected using ATP-ase staining [4,32].
The cause of the shift from type üb to type IIx fibres 
following burst therapy is not entirely clear. This shift 
may be caused by a disappearance of type Hb fibres com­
bined with an appearance of new type IIx fibres. The 
following observations, however, support the occurrence 
of a transformation from type üb to Hx fibres. Corticoste­
roids decrease the rate of amino acid incorporation into 
the MyHCs, resulting in a decreased turnover rate of the 
MyHCs in the muscle cell. As this decrease in turnover 
rate is most pronounced in the fast twitch muscle fibres 
[5], type üb fibres are likely to be affected most. This 
may lead to a decrease in Hb MyHCs in type üb fibres. 
Since genes of Hx MyHCs are coexpressed in a number 
of type üb muscle fibres [34], an increase of Hx MyHCs 
in type Hb muscle fibres may occur to compensate for 
the decrease in type Hb MyHCs. To our knowledge, there 
is no evidence that type Hb fibres disappear while new 
type Hx fibres are generated. The shift from type Hb to 
type Hx fibres following MP burst therapy is probably 
too small to cause functional changes at different stimu­
lation frequencies.
Biochemistry
Treatment with MP resulted in a decrease in energy 
supply, as indicated by a reduction in CK activity or in 
glycogenolytic activity. This impairment in energy sup­
ply may have caused the increase in oxidative capacity 
in all MP groups. To what extent these differences in 
biochemistry were influenced by the fact that animals in 
the MP-A and MP-B group received 2 mg-kg“1 MP 23 
to 30 h before investigation, whereas, animals in the MP- 
C group only received 1 mg-kg4 , is not clear.
Creatine kinase rapidly rephosphorylates adenosine 
diphosphate (ADP) from phosphocreatine in order to keep 
a constant adenosine triphosphate (ATP) level in the mus­
cle. A decrease in CK activity may, therefore, lead dir­
ectly to a reduction in fast energy supply. CK activity 
decreased following steroid administration in bursts com­
pared to MP-C. In patients with bronchial asthma, CK 
activity in the deltoid muscle decreased following pred­
nisone treatment (17 mg-day1 for 15 yrs) [8].
The increase in glycogen storage in the diaphragm mus­
cle following steroid administration found by F erg u so n  
et al. [35] may be the result of a decrease in glycogen 
breakdown, or an increase in glycogen production [7], 
or both [8]. Our data show that altemate-day and burst 
therapy did not affect glycogenolytic capacity, measured 
by phosphorylase activity, in contrast to continuous steroid 
administration.
Since the diaphragm muscle possesses a high ß-oxida­
tion capacity [36], it is unclear whether the 20% reduction 
in HADH activity, observed following steroid adminis­
tration in bursts, has functional consequences. Short-term 
(10 days) prednisolone treatment (5 mg-kg"1 daily s.c.) 
did not change HADH activity in rat diaphragm [9]. 
However, a decrease in HADH activity in vastus later­
alis muscle of patients with rheumatoid arthritis occurred 
with low doses of prednisolone [37].
In the present study, administration of methylpred­
nisolone resulted in an increase in oxidative capacity, as 
indicated by the increased CS activity, independent of 
the treatment regimen applied. This is in line with the in­
crease in oxidative staining reaction in skeletal muscle 
reported by others [10]. Mitochondrial changes in rabbit 
diaphragm, following glucocorticoid administration, 
ranged from a numerical increase to the presence of 
enlarged and degenerated mitochondria [38]. In contrast 
to these observations, CS activity in rat diaphragm was 
reduced following 5 mg-kg-1 prednisolone daily for 10 
days. However, no changes in CS activity were repor­
ted following 0.5, 1 or 2 mg-kg*1 daily [9], suggesting 
that enzyme activity was affected more using high dos­
ages of prednisolone in comparison to low dosages. 
Reactions of metabolism to corticosteroids may also 
depend on the fibre type composition of the muscle [9, 
35], because the resistance of different fibre types is 
believed to depend on their ability to compensate the 
steroid-induced deficiency of the glycogenolytic route by 
converting to oxidative metabolism [10].
In conclusion, force generation decreased in all methyl­
prednisolone treated groups to an equal extent, although 
the methylprednisolone treatment regimens affected dia­
phragm muscle morphology and bioenergetic enzyme 
activities in a different way.
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